Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3
暂无分享,去创建一个
[1] P. Carroll,et al. Cell type–specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors , 2015, Science Signaling.
[2] R. Tomasini,et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance , 2015, EMBO molecular medicine.
[3] N. Sonenberg,et al. Targeting the translation machinery in cancer , 2015, Nature Reviews Drug Discovery.
[4] Feng Zhang,et al. Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.
[5] T. Alain,et al. The ever-evolving role of mTOR in translation. , 2014, Seminars in cell & developmental biology.
[6] S. Cook,et al. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation , 2014, Journal of Cell Science.
[7] J. Martina,et al. The Nutrient-Responsive Transcription Factor TFE3 Promotes Autophagy, Lysosomal Biogenesis, and Clearance of Cellular Debris , 2014, Science Signaling.
[8] N. Sonenberg,et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. , 2013, Cell metabolism.
[9] David A. Scott,et al. Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.
[10] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[11] N. Sonenberg,et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. , 2012, Cancer research.
[12] Philippe P Roux,et al. Regulation of mRNA translation by signaling pathways. , 2012, Cold Spring Harbor perspectives in biology.
[13] N. Sonenberg,et al. Translational homeostasis via the mRNA cap-binding protein, eIF4E. , 2012, Molecular cell.
[14] S. Thorgeirsson,et al. mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma , 2012, Science Translational Medicine.
[15] T. Walther,et al. The Transcription Factor TFEB Links mTORC1 Signaling to Transcriptional Control of Lysosome Homeostasis , 2012, Science Signaling.
[16] Stan J. J. Brouns,et al. RNA in defense: CRISPRs protect prokaryotes against mobile genetic elements. , 2012, Cold Spring Harbor perspectives in biology.
[17] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[18] D. Sabatini,et al. A unifying model for mTORC1-mediated regulation of mRNA translation , 2012, Nature.
[19] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[20] Nicholas T. Ingolia,et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.
[21] A. Ballabio,et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB , 2012, The EMBO journal.
[22] P. Dagur,et al. The EIF4EBP3 translational repressor is a marker of CDC73 tumor suppressor haploinsufficiency in a parathyroid cancer syndrome , 2012, Cell Death and Disease.
[23] M. Hall,et al. Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.
[24] D. Fisher,et al. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] N. Ilić,et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis , 2011, Proceedings of the National Academy of Sciences.
[26] S. Shurtleff,et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Michael A. Choti,et al. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.
[28] E. D. de Vries,et al. Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[29] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[30] N. Sonenberg,et al. mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs , 2010, Science.
[31] Philippe Pierre,et al. SUnSET, a nonradioactive method to monitor protein synthesis , 2009, Nature Methods.
[32] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[33] A. Hinnebusch,et al. Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets , 2009, Cell.
[34] Robbie Loewith,et al. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.
[35] J. Mandell. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality , 2008, Histochemistry and Cell Biology.
[36] Suzanne F. Jones,et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Franck Molina,et al. A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer , 2008, Clinical Cancer Research.
[38] J. Graff,et al. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. , 2008, Cancer research.
[39] V. Mootha,et al. mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.
[40] N. Sonenberg,et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.
[41] J. Baselga,et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. , 2007, Cancer research.
[42] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[43] M. Ladanyi,et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.
[44] J. Baselga,et al. 4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis , 2007, Clinical Cancer Research.
[45] J. Lawrence,et al. Activation of Mammalian Target of Rapamycin (mTOR) by Insulin Is Associated with Stimulation of 4EBP1 Binding to Dimeric mTOR Complex 1* , 2006, Journal of Biological Chemistry.
[46] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[47] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[48] H. Sone,et al. TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes , 2006, Nature Medicine.
[49] D. Guertin,et al. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.
[50] Nahum Sonenberg,et al. Gene Fusion and Overlapping Reading Frames in the Mammalian Genes for 4E-BP3 and MASK* , 2003, Journal of Biological Chemistry.
[51] M. Ladanyi,et al. Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions: A Sensitive and Specific Immunohistochemical Assay , 2003, The American journal of surgical pathology.
[52] N. Sonenberg,et al. A Novel Role of the Mammalian GSPT/eRF3 Associating with Poly(A)-binding Protein in Cap/Poly(A)-dependent Translation* , 2002, The Journal of Biological Chemistry.
[53] J. Avruch,et al. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.
[54] D. Sabatini,et al. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.
[55] C. Proud,et al. Caspase Cleavage of Initiation Factor 4E-Binding Protein 1 Yields a Dominant Inhibitor of Cap-Dependent Translation and Reveals a Novel Regulatory Motif , 2002, Molecular and Cellular Biology.
[56] M. Ladanyi,et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.
[57] A. Gingras,et al. Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.
[58] P. J. Welch,et al. Involvement of Proteasome α-Subunit PSMA7 in Hepatitis C Virus Internal Ribosome Entry Site-Mediated Translation , 2001, Molecular and Cellular Biology.
[59] Alfons Meindl,et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.
[60] A. G. Kessel,et al. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins , 2000, Oncogene.
[61] S. Gygi,et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.
[62] C. Goding,et al. Targeting the Microphthalmia Basic Helix-Loop-Helix–Leucine Zipper Transcription Factor to a Subset of E-Box Elements In Vitro and In Vivo , 1998, Molecular and Cellular Biology.
[63] H. Lodish,et al. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. , 1998, Genes & development.
[64] A. Gingras,et al. 4E-BP3, a New Member of the Eukaryotic Initiation Factor 4E-binding Protein Family* , 1998, The Journal of Biological Chemistry.
[65] Damian Smedley,et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma , 1997, Oncogene.
[66] James A. Vaught,et al. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. , 1994, Genes & development.
[67] A. Gingras,et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function , 1994, Nature.
[68] B. Haber,et al. Characterization of a Human Pancreatic Carcinoid in Vitro: Morphology, Amine and Peptide Storage, and Secretion , 1994, Pancreas.